Published in Br J Surg on August 01, 1972
Systemic complement activation in psoriasis vulgaris. Clin Exp Dermatol (1996) 1.94
Tanning with ultraviolet A sunbeds. BMJ (1990) 1.93
Postoperative depression of tumour-directed cell-mediated immunity in patients with malignant disease. Br Med J (1972) 1.84
Juvenile plantar dermatosis: a new entity?. Clin Exp Dermatol (1976) 1.51
Assessment of an anti-T-cell receptor variable region antibody panel in cutaneous T-cell lymphoma. Br J Dermatol (1994) 1.39
The suitability of SunCheck patches and Tanscan cards for monitoring the sunburning effectiveness of sunlight. Br J Dermatol (1993) 1.38
Health and the ozone layer. BMJ (1988) 1.37
UVA-induced melanocytic lesions. Br J Dermatol (1987) 1.35
Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol (1984) 1.14
Site-specific melanocytic naevus counts as predictors of whole body naevi. Br J Dermatol (1988) 1.09
Assessment of prognosis in patients with malignant melanoma. Lancet (1972) 1.05
Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol (1994) 1.04
Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol (1990) 1.04
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Clinical accuracy of the diagnosis of cutaneous malignant melanoma. Br J Dermatol (1998) 1.03
Cell-mediated immunity in patients with malignant melanoma. Br J Dermatol (1972) 0.99
Loss of beta2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Br J Dermatol (1981) 0.98
Sensitization to tumour-associated antigens in human breast carcinoma. Int J Cancer (1974) 0.97
Seven-point checklist for melanoma. Clin Exp Dermatol (1991) 0.96
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93
The spectrum of mutations in erythrokeratodermias--novel and de novo mutations in GJB3. Hum Genet (2000) 0.93
An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol (1998) 0.92
Severe reaction to diphosphonate: implications for treatment of Paget's disease. BMJ (1988) 0.89
Leukocyte migration inhibition by cancer patients' sera. Int J Cancer (1976) 0.89
Serum anti-tumour antibodies and auto-antibodies in vitiligo. Br J Dermatol (1975) 0.88
The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol (1998) 0.88
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol (1996) 0.87
Tioconazole nail solution--an open study of its efficacy in onychomycosis. Clin Exp Dermatol (1985) 0.87
Plantar malignant melanoma in a white Caucasian population. Br J Dermatol (1993) 0.87
Letter: Formalin-fixed tumour cells in the leukocyte migration test. Lancet (1973) 0.86
An audit of the completeness of non-melanoma skin cancer registration in Greater Glasgow. Br J Dermatol (1997) 0.86
Lupus erythematosus in association with finger-clubbing. Br J Dermatol (1973) 0.85
Pustular psoriasis in association with renal amyloidosis. Br J Dermatol (1974) 0.85
An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltrates. Br J Dermatol (1986) 0.85
The effect of treatment with 13-cis-retinoic acid on the metabolic burst of peripheral blood neutrophils from patients with acne. Br J Dermatol (1991) 0.85
Natural-killer-cell activity in atopic dermatitis. Clin Allergy (1984) 0.83
The relationship between immunological parameters and response to therapy in resistant oral candidosis. Br J Dermatol (1978) 0.83
Formalinized tumour cells in the leucocyte migration inhibition test. Clin Exp Immunol (1975) 0.83
Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne. Br J Dermatol (1992) 0.82
Plasma zinc in psoriatic in-patients treated with local zinc applications. Br J Dermatol (1980) 0.81
Indirect leukocyte migration assay in patients with malignant melanoma. Int J Cancer (1979) 0.80
The use of a double-label immunoperoxidase monoclonal antibody technique in the investigation of patients with mycosis fungoides. Br J Dermatol (1982) 0.80
Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment. Yale J Biol Med (1973) 0.80
A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol (1982) 0.80
The unexpected sites of melanoma regional recurrences. J Plast Reconstr Aesthet Surg (2006) 0.79
An examination of the immunology of cancer patients. Int J Cancer (1976) 0.79
The role of sunlight in the aetiology of cutaneous malignant melanoma. Clin Exp Dermatol (1981) 0.79
The effect of topical steroid application on natural killer cell activity. Clin Exp Allergy (1989) 0.79
Personal solar UV-A doses received by patients undergoing oral psoralen photochemotherapy for psoriasis. Br J Dermatol (1981) 0.79
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions. Histopathology (1991) 0.79
Human melanoma cell-derived factor(s) stimulate fibroblast glycosaminoglycan synthesis. Int J Cancer (1992) 0.79
Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy. Br J Dermatol (1994) 0.79
The contribution of direct immunofluorescence to the diagnosis of lupus erythematosus. J Cutan Pathol (1989) 0.79
In vitro reaction of cancer patients and others to Bacillus Calmette-Gueérin. Int J Cancer (1980) 0.79
Novel variants of human papillomavirus type 2 in warts from immunocompromised individuals. Br J Dermatol (1989) 0.78
Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. J Clin Pathol (1990) 0.78
The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Scottish Melanoma Group. Br J Cancer (1991) 0.78
The use of paraffin-processed tissue and the immunoperoxidase technique in the diagnosis of bullous diseases, lupus erythematosus and vasculitis. Br J Dermatol (1982) 0.78
A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol (1984) 0.78
A quantitative analysis of the Langerhans cell in chronic plaque psoriasis. Clin Exp Dermatol (1986) 0.77
Cellular immunity in human malignant melanoma and melanoma histology. Br J Cancer (1973) 0.77
Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br J Cancer (1997) 0.77
Pyoderma gangrenosum in infancy. Acta Derm Venereol (1982) 0.77
Retinoic acid-induced inhibition of metastatic melanoma cell lung colonization and adhesion to endothelium and subendothelial extracellular matrix. Clin Exp Metastasis (1992) 0.77
Out-patient treatment of psoriasis: short contact and overnight dithranol therapy compared. Br J Dermatol (1985) 0.76
Management of cutaneous T cell lymphoma. BMJ (1994) 0.75
The melanoma epidemic. Excess exposure to ultraviolet light is established as major risk factor. BMJ (1996) 0.75
Cellular immunity to breast carcinoma and malignant melanoma. Br J Cancer Suppl (1973) 0.75
Comparative study of three methods of plastic embedding in diagnostic dermatopathology. J Clin Pathol (1985) 0.75
Topical econazole in cutaneous fungal infections. Practitioner (1980) 0.75
Localized secondary telangiectasia in patients with thyroid disease. Br J Dermatol (1973) 0.75
Wiskott-Aldrich syndrome with partial response to transfer factor. Br J Dermatol (1978) 0.75
Immunological changes in cancer patients receiving BCG. Dev Biol Stand (1978) 0.75
Perspectives in dermatology: Great Britain (1972-1974). Int J Dermatol (1975) 0.75
Porphyria cutanea tarda and hyperkeratosis. Br J Clin Pract (1972) 0.75
Current trends in the management of recurrent malignant melanoma. Clin Exp Dermatol (1977) 0.75
Onycholysis occurring during PUVA therapy. Clin Exp Dermatol (1979) 0.75
Malignant melanoma and the Scottish Melanoma Group. Health Bull (Edinb) (1986) 0.75
The mechanism of tumour cell induced inhibition of human leucocyte migration. Eur J Cancer (1979) 0.75
Cutaneous lymphadenoma: a case report and review of the literature. Br J Dermatol (1993) 0.75
The labial melanotic macule: a review of 79 cases. Br J Dermatol (1997) 0.75
The immune response in human malignant melanoma. Clin Exp Dermatol (1976) 0.75
Re-examining crude coal tar treatment for psoriasis. Br J Dermatol (1992) 0.75
Evaluation and staging in the Scottish Dermatological Society mycosis fungoides register. Bull Cancer (1977) 0.75
Proceedings: Immunity in patients with breast cancer. Br J Cancer (1975) 0.75
Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy. Clin Exp Dermatol (1986) 0.75
Generalized eruptive histiocytoma. Br J Dermatol (1992) 0.75
Etretinate and visual function: a 1-year follow-up study. Br J Dermatol (1991) 0.75
Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol (1987) 0.75
The management of cutaneous malignant melanoma. Clin Exp Dermatol (1982) 0.75
Histological changes observed in the skin of patients with mycosis fungoides receiving photochemotherapy. Clin Exp Dermatol (1980) 0.75
Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol (1985) 0.75
Ultraviolet B radiation was increased at ground level in scotland during a period of ozone depletion. Br J Dermatol (1997) 0.75
Proceedings: Some aspects of the use of B.C.G. in the treatment of advanced malignant disease. Br J Cancer (1974) 0.75
Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma. Br J Surg (1995) 0.75
A case of focal dermal hypoplasia. Clin Exp Dermatol (1982) 0.75
Juvenile plantar dermatosis--an 8-year follow-up of 102 patients. Clin Exp Dermatol (1987) 0.75
Not wanted at thirty-five. Lancet (1979) 0.75
Proceedings: cellular immunity to malignant melanoma. Br J Surg (1973) 0.75
Studies in cutaneous immunofluorescence. I. The effect of storage time on direct immunofluorescence of skin biopsies from bullous disease and lupus erythematosus. J Cutan Pathol (1980) 0.75